Cumulative Index 1990

Volume 17

February	I. UROLOGIC PEARLS
	II. UPDATE ON URINARY STONE DISEASE, pages 1–246
May	PEDIATRIC URINARY TRACT OBSTRUCTION, pages 247–460
August	BENIGN PROSTATIC HYPERPLASIA, pages 461–688
November	EARLY DETECTION AND TREATMENT OF LOCALIZED CARCINOMA OF THE PROSTATE, pages 689–920

Note: Page numbers of issue and article titles are in **boldface** type.

Acetohydroxamic acid, for struvite calculi, 165
Acid-base balance, vesicoureteral reflux and, in children, 311–312
Alfuzosin, for benign prostatic hyperplasia, clinical trials of, 646
Allopurinol, for calcium calculi, 167
Alpha-adrenergic antagonists, for neurogenic bladder dysfunction, in children, 400
Alpha-adrenergic blockers, for benign prostatic hyperplasia, **641–649**, **651–659**
  autonomic innervation of prostate and, 641–642
  clinical experience with, 643–646
  effectiveness of, 654–656
    vs. prostatectomy, 656
  indications and contraindications for, 646–647
  patient selection for, 657
  rationale for, 643
  role of, 652–653
  side effects and dosage of, 646
  significance of prostatic autonomic receptors and, 642–643
Alpha-fetoprotein, in diagnosis of prenatal hydronephrosis, 248
Alpha-mercaptopropionylglycine, for cystine calculi, 164
Aminoglycoside antibiotics, nephrotoxicity of, 146–148
Amniotic fluid, in diagnosis of prenatal hydronephrosis, 248
Amphotericin B, nephrotoxicity of, 148–149
Analgesics, nephrotoxicity of, 150–151
Androgen ablation and blockade, for benign prostatic hyperplasia, **661–670**
  5α-reductase inhibitor therapy, finasteride, 667–669
  antiandrogen therapy in, 664–666
    cyproterone acetate, 665–666
    flutamide, 666
    medical castration, 665
    progestational agents, 666
    surgical castration, 664–665
  normal androgen physiology and, 662–664
  reductase inhibitor therapy, 666–669
  role of androgen in benign prostatic hyperplasia, 661–662
Antiandrogen therapy, after treatment failure, for prostatic cancer, 845
Antibiotics, aminoglycoside, nephrotoxicity of, 146–148
Anticholinergics, for neurogenic bladder dysfunction, in children, 402
  for posterior urethral valves, in children, 384, 385
Antimicrobials, for transurethral prostatectomy, for benign prostatic hyperplasia. See *Transurethral prostatectomy.*
Arteriography, of urolithiasis, 187–188
Atropine, for neurogenic bladder dysfunction, in children, 400
Augmentation cystoplasty, for neurogenic bladder dysfunction, in children, 401
Azotemia, benign prostatic hyperplasia and, 511, 523
  posterior urethral valves and, in children, 365–367

Bacteremia, in transurethral prostatectomy, sources and incidence of, 595–596
Bacteriuria, in transurethral prostatectomy, sources and incidence of, 595–596
Balloon dilatation, for benign prostatic hyperplasia, **671–677**
  anesthesia for, 672
  deflation and postoperative management of, 674
  historical aspects of, 671
  mechanism of action of, 672
  patient selection for, 674–675
  results of, 675–676
  technique for, 672–674
  technology in, 671–672
  for ureteropelvic junction obstruction, in children, 420
  of spermatic veins, for varicoceles, 900, 902
  transurethral, of prostate, anesthesia in, **55–56**
Barretta Laso, for intracavernous vasoactive drugs, **19–21**
Bed Utility Grip, urologic uses of, **139–140**
Benign prostatic hyperplasia, alpha-adrenergic blockers for. See *Alpha-adrenergic blockers.*
  and risk of prostatic cancer, 713

Benign prostatic hyperplasia *(Continued)*
androgen ablation and blockade for. See *Androgen ablation and blockade.*
balloon dilatation for. See *Balloon dilatation.*
biology of, 483–485
clinical features of, 509–513
azotemia, 511, 523
diminished functional bladder capacity, 511–513
residual urine, 511
urinary retention, 510
clinical studies of, 461–464
influence of aging endocrine factors, 462–463
influence of reversible testicular suppression, 461–462
steroid hormones and receptor content, 463–464
diagnostic imaging of, **517–536**
computed tomography in, 530
magnetic resonance imaging in, 530–532
plain film and intravenous urography in, 520–523
ultrasonography in, 524, 526–530
voiding cystourethrography and retrograde urethrography in, 523–524
differential diagnoses of, 511
epidemiology of, 495–501
body habitus in, 500
definitions in, 495–496
diet in, 499–500
occurrence parameters and relation to age, 496–498
other disease and medications in, 500
race and nationality in, 498–499
religion in, 500
experimental studies of, 464–473
androgen and estrogen stimulation, 467–470
cell death vs. cell growth, 470, 472–473
stromal and epithelial pathology, 465–467
multichannel urodynamic studies of. See *Multichannel urodynamic studies.*
natural history of, 501–505, 509–510
cohort studies of, 501–502
definitions in, 501
placebo arms of drug trials, 502–503
probability of complications in, 503–505
pathology of, **477–486**
anatomic location in, 477–479
animal models of, 485–486
features of evolution, 480–482
features of origin, 479–480
morphometry of resection specimens, 482–483
prostatectomy for, incidence of stage A prostatic cancer in, 567–568
symptoms of, 510–511
therapy for, indications for, 513–515
transurethral prostatectomy for. See *Transurethral prostatectomy.*
treatment response to drugs in, **631–640**
appropriate and sensitive evaluation methods in, 632–633
corollaries of, 634–635
cystoscopy of, 637
double-blind and placebo-controlled studies of, 633–634
elimination of bias in, 632
filling cystometry of, 638–639
initial considerations in, 631–632
pressure-flow studies of, 639
prostate size in, 637
residual urine and, 638
sample size in, 632
statistical and clinical significance of, 634
symptoms in, 635–636
uroflowmetry of, 637–638
urinary flow rates in. See *Uroflowmetry.*
Biliary tract, extracorporeal shock wave lithotripsy in, 235–237
Biopsy, of clinically occult prostatic cancer, 570–571
Bladder, abnormalities of, and lower urinary tract obstruction, in children, 331–333
catheter drainage of, in female children, 2–3
Low-Profile Balloon Catheter in, **111–113**
decompensation of, benign prostatic hyperplasia and, 504–505
diminished functional capacity of, benign prostatic hyperplasia and, 511–513
in prune belly syndrome, in children, 408
neurogenic dysfunction of. See *Neurogenic bladder dysfunction.*
Bladder augmentation, for posterior urethral valves, in children, 384, 385, 386
Bladder neck, obstruction of, in prostatic cancer, hormone therapy for, 857
Bladder outlet, in voiding function, 555
obstruction of, diagnosis of, 606
experimental models of, 440–441
in children, 331–332
in neurogenic bladder dysfunction, in children, 397
Bladder procedures, percutaneous. See *Cystotomy.*
Bleeding, transurethral prostatectomy and, for benign prostatic hyperplasia, 582
Blocksom procedure, for posterior urethral valves, in children, 340
for urethral strictures, in children, 392
Bone scans, to stage prostatic cancer, 854

Cadmium, intake of, and risk of prostatic cancer, 714
Calcium calculi, diagnostic imaging of, 176–177
laser lithotripsy for, 227
metabolic evaluation of, 159–161, 165
treatment of, 167
Calculi. See also *Stone disease; Urolithiasis.*
calcium. See *Calcium calculi.*
caliceal, treatment of, 195–196
combination, treatment of, 203
cystine. See *Cystine calculi.*
renal. See *Renal calculi.*
staghorn, treatment of, 196–198
ureteral. See *Ureteral calculi.*
ureteroileal, treatment of, 202–203
Caliceal calculi, treatment of, 195–196
Caliceal diverticula, and infundibular stenosis with stones, treatment of, 194–195
Cancer, colonic. See *Colonic cancer.*
testicular. See *Testicular cancer.*
prostatic. See *Prostatic cancer.*
Candela laser therapy, for ureteral calculi, 201, 219–220, 226–227
Carboplatin, nephrotoxicity of, 151–152
Castration, for benign prostatic hyperplasia, effects of, 664–665
Catheterization, bladder, Low-Profile Balloon Catheter in, 235–237
of female children, 2–3
clean intermittent, for neurogenic bladder dysfunction, in children, 399–400, 402
for posterior urethral valves, in children, 384, 385
indwelling urethral, patient comfort in, **23–24**
Cavernosography, of impotence, due to prostatectomy, for benign prostatic hyperplasia, 617
Cavernosometry, of impotence, due to prostatectomy, for benign prostatic hyperplasia, 617

Cavernous arteries, evaluation of, in impotence, due to prostatectomy, for benign prostatic hyperplasia, 616–617
Cell receptors, analysis of, in prostatic cancer, stage D1, 880–881
Chemolysis, for ureteral calculi, 221, 223
Chemotherapy, for prostatic cancer, stage D1, 879–880
  with radiotherapy, 878
  nephrotoxicity of, 151–152
Cisplatin, nephrotoxicity of, 151–152
Cohen technique, for implantation of revised megaureters, in children, 298, 301
Coil embolization, of spermatic veins, for varicoceles, 902
Cold knife incision, for ureteropelvic junction obstruction, in children, 420–421
Colonic cancer, resectoscope in, **63–66**
  case reports of, 64–65
  technique for, 63–64
Colostomy, radical prostatectomy and, for prostatic cancer, 728
  radiotherapy and, for prostatic cancer, 728
Computed tomography, of benign prostatic hyperplasia, 530
  of prostatic cancer, as staging device, 855
  of urolithiasis, 185–186
Congenital obstructive uropathy, experimental, **437–447**
  criticisms of, 441–444
  future directions in, 445
  goals of, 438
  implications of findings in, 444–445
  models and results of, 438–441
    for bladder outlet obstruction, 440–441
    for ureteral obstruction, 439–440
  unique features of, 437–438
Constant-flow resectoscope, in transurethral prostatectomy, for benign prostatic hyperplasia, 580
Contrast media, radiographic, nephrotoxicity of, 149–150
Cyclosporine, nephrotoxicity of, 152–154
Cyproterone acetate, for benign prostatic hyperplasia, effects of, 665–666
Cystectomy, radical, control of dorsal vein complex in, **49–53**
  technique for, 49–51
Cystine calculi, chemolysis of, 221, 223
  diagnostic imaging of, 177
  metabolic evaluation of, 162
  percutaneous procedures for, 211–212
  treatment of, 164, 192–193
Cystinuria, heterozygous, metabolic evaluation of, 161
Cystometry, filling, of benign prostatic hyperplasia, 545
  for treatment response to drugs, 638–639
  for posterior urethral valves, in children, 355
Cystoplasty, augmentation, for neurogenic bladder dysfunction, in children, 401
Cystoscopy, of benign prostatic hyperplasia, for treatment response to drugs, 637
Cystotomy, Low-Profile Balloon Catheter in, **111–113**
  percutaneous suprapubic, **67–73**
    anatomy in, 67
    case reports of, 68–70
    endoscopic technique for, 68
    fluoroscopic technique for, 68
    indications and contraindications for, 67–68
    uses of, 70
Cystourethrography, voiding, of benign prostatic hyperplasia, 523–524

Detrusor, in micturition, 554–555
Detrusor instability, benign prostatic hyperplasia and, 511–513
  in children, 332
Detrusor pressure, in neurogenic bladder dysfunction, in children, 396
Detrusor-sphincter dyssynergia, in neurogenic bladder dysfunction, in children, 402
Detrusor storage capacity, posterior urethral valves and, in children, 346–347
Diabetes insipidus, nephrogenic, and bladder capacity, in children, 385–386
Diethylstilbestrol, for prostatic cancer, stage D1, 873
Digital rectal examination, of benign prostatic hyperplasia, 514
  of prostatic cancer, **739–744**
    after radical prostatectomy, 816
    clinically occult, 570
    complications of, 742–743
    economics of, 724, 727
    limitations of, 740–741
    requirements of, 741–742
    stage B, transrectal ultrasonography as adjunct to, 783–784
Dimercaptosuccinic acid, in diuretic renography, 280–282
Diuretic renography, of hydronephrosis, in children, 270–271, 274–279
    disadvantages of, 293–294
    interpretation of, 277–279
    protocol for, 275–277
    radiopharmaceutical for, 274–275
  of obstructing ectopic ureteroceles, in children, 318–319
  of posterior urethral valves, in children, 368
Diverticula, caliceal, and infundibular stenosis with stones, treatment of, 194–195
Dornier HM3 lithotripter, clinical results with, 234
Dorsal lithotomy, modified stirrups for, **131–133**
Doxazosin, for benign prostatic hyperplasia, clinical trials of, 653–654
Duplex systems, in children, upper-pole heminephroureterectomy for. See *Heminephroureterectomy.*

Ejaculation, posterior urethral valves and, in children, 377
Electrocautery, for ureteropelvic junction obstruction, in children, 420–421
Electrohydraulic lithotripsy, for ureteral calculi, 201, 220, 227–228
Electromyography, of neurogenic bladder dysfunction, in children, 398
Endocrine therapy, for prostatic cancer, stage D1, 873–874
  with surgery, 874–876
Endopyelotomy, for ureteropelvic junction obstruction, in children, 421, 422, 423–426
  complications of, 425–426
End-stage renal disease, posterior urethral valves and, in children, 356–357
Epididymitis, prevention of, after transurethal prostatectomy, for benign prostatic hyperplasia, 581
Erection, artificial, hematomas during, prevention of, **17**
Extracorporeal shock wave lithotripsy, **231–242**
  bioeffects of, 237–239
    animal studies of, 237–238
    clinical studies of, 238–239
    in vitro studies of, 237
  clinical results of, 234–235
  for caliceal calculi, 195–196

Extracorporeal shock wave lithotripsy *(Continued)*
for caliceal diverticula and infundibular stenosis with stones, 194–195
for cystine calculi, 192
for horseshoe kidneys, 198
for pediatric stone disease, 203
for pelvic kidneys, 198
for renal calculi, in children, 212
for renal pelvic stones other than staghorn calculi, 193–194
for staghorn calculi, 196–198, 209
for ureteral calculi, 198–202, 217–219, 224, 228–229
for uric acid calculi, 193
in biliary tract, 235–237
instrumentation for, 231–234
to couple shock waves, 233
to focus shock waves, 233
to generate electrohydraulic shock waves, 232
to generate electromagnetic shock waves, 233
to generate piezoelectric shock waves, 232–233
to localize stones, 233–234

Fertility, posterior urethral valves and, in children, 377
Filling cystometry, of benign prostatic hyperplasia, 545
for treatment response to drugs, 638–639
Finasteride, for benign prostatic hyperplasia, effects of, 667–669
Fistulas, lower urinary tract, endoscopic ureteral occlusion for, **103–105**
results of, 104–105
technique for, 103–104
Flaps, for urethral strictures, in children, 393
Flow cytometry, in prostatic cancer, **885–891**
cytochemical stains in, 886–887
DNA content in, 887
light scatter in, 889
principles of, 885–886
specificity of, 887
stage D1, 880
to assess prognosis, 888
to measure prostatic acid phosphatase, 889
to monitor patient response, 888–889
Flutamide, for benign prostatic hyperplasia, effects of, 666

Genital examination, in female children, 1–2
Glomerular filtration rate, and nephrotoxicity of urologic drugs, 146
vesicoureteral reflux and, in children, 309–310
Gold-198, in radiotherapy, for prostatic cancer, 861
Gonadotropin releasing hormone agonists, for benign prostatic hyperplasia, effects of, 665
Goodwin sound, for urethral strictures. See *Urethra*.
Grafts, for urethral strictures, in children, 393
Greenberg surgical support system, **107–109**
instrument design in, 107–108
Growth, inadequacy of, posterior urethral valves and, in children, 357

Hegar dilators, in transurethral resection of prostate, **57–58**
Hematomas, during artificial erection, prevention of, **17**
subcapsular, electrohydraulic lithotripsy and, 238–239
Hematuria, benign prostatic hyperplasia and, 514
Hemiacidrin, for staghorn calculi, 198
for struvite calculi, 164, 221

Heminephroureterectomy, for duplex systems in children, **115–119**
easy method of, 117–119
pathology in, 115
potential complications of, 115
technique for, 115–117
Hemolytic uremic syndrome, cyclosporine and, 154
Hormone therapy, after treatment failure, for prostatic cancer, 845
for impotence, due to prostatectomy, for benign prostatic hyperplasia, 617
for prostatic cancer, stage C, 857–858
stage D1, 872–873
with radiotherapy, 878
Horseshoe kidneys, treatment of, 198
Hydronephrosis, in children, in-office ultrasonography of, 429–432
as screening process, 430
to clarify etiology, 430
to evaluate postoperatively, 430
to expedite diagnosis, 429–430
to identify incorrect diagnoses, 430, 432
posterior urethral valves and, 364–365
ureteropelvic junction obstruction and, 264–266
postnatal management of, 260–261
prenatal diagnosis and management of, **247–262**
amniotic fluid in, 248
elevated maternal alpha-fetoprotein in, 248
ethical considerations in, 259–260
for duplex anomalies of upper urinary tract, 249, 252
for polyhydramnios, 249
for posterior urethral valves, 252–253
for prune belly syndrome, 253
for ureteropelvic junction obstruction, 249
for ureterovesical junction obstruction, 249
for vesicoureteral reflux, 252
indications for, 258–259
occurrence and outcomes of, 253–257
results of, 257–258
ultrasonography in, 247–248
Hypercalciuria, metabolic evaluation of, 160
Hyperoxaluria, metabolic evaluation of, 160–161
Hypertension, cyclosporine and, 153, 154
extracorporeal shock wave lithotripsy and, 239
posterior urethral valves and, in children, 357–358
Hyperuricosuria, metabolic evaluation of, 160
treatment of, 163–164
Hypocitraturia, metabolic evaluation of, 161
Hypomagnesuria, metabolic evaluation of, 161

Ileal conduit, enhancement of, **125–129**
techniques to correct ileocutaneous stomal stenosis, 128–129
techniques to ensure short ileal conduit, 125–126
techniques to shorten ileal conduit through peristomal incision, 126–128
Imipramine hydrochloride, for neurogenic bladder dysfunction, in children, 400
Impotence, prostatectomy and, for benign prostatic hyperplasia, 583, **613–620**
arterial revascularization for, 619
evaluation of cavernous arteries in, 616–617
evaluation of penile veins in, 617
hormonal therapy for, 617
incidence of, 614–615
mechanisms of erectile failure, 615
penile erection physiology in, 613–614
penile prostheses for, 619–620

Impotence *(Continued)*
penile vein incision and ligation for, 619
pharmacologic evaluation of, 616
prevention of, 615
psychotherapy for, 617
vacuum erection devices for, 618–619
vasoactive substances for, 617–618
radical prostatectomy and, for prostatic cancer, 728
radiotherapy and, for prostatic cancer, 728
Incontinence, urinary. See *Urinary incontinence.*
Indoramin, for benign prostatic hyperplasia, clinical trials of, 646
Infections, transurethal prostatectomy and, for benign prostatic hyperplasia, 582
antimicrobials for. See *Transurethral prostatectomy.*
urinary tract, benign prostatic hyperplasia and, 504
posterior urethral valves and, in children, 349, 363–364
vesicoureteral reflux and, in children, 313
Infundibular stenosis, and caliceal diverticula with stones, treatment of, 194–195
Intravenous urography, of benign prostatic hyperplasia, 520–523
of urolithiasis, 177–180
Iodine-125. See *Radiotherapy.*
Irrigating fluids, in transurethral prostatectomy, for benign prostatic hyperplasia, 581–582

Kidney failure, benign prostatic hyperplasia and, 504
Kidney stones. See *Renal calculi.*
Kidneys, failure of, posterior urethral valves and, in children. See *Posterior urethral valves.*
functional changes in, vesicoureteral reflux and, in children. See *Vesicoureteral reflux.*
horseshoe, treatment of, 198
pelvic, treatment of, 198
Krauss arm support, for dorsal lithotomy, **131–133**
KUB films, of benign prostatic hyperplasia, 520–523
of urolithiasis, 174–177

Laser therapy, for ureteral calculi, 201, 219–220, 226–227
Lithotripsy, electrohydraulic, for ureteral calculi, 201, 220, 227–228
extracorporeal shock wave. See *Extracorporeal shock wave lithotripsy.*
laser, for ureteral calculi, 226–227
percutaneous, for renal calculi. See *Renal calculi.*
percutaneous ultrasonic, for ureteral calculi, 225–226
supracostal approach for, **99–102**
anatomy in, 99
complications of, 100–101
technique for, 99–100
Low-Profile Balloon Catheter, for drainage of bladder and renal pelvis, **111–113**
Lungs, development of, posterior urethral valves and, in children, 349–350
Luteinizing hormone, in benign prostatic hyperplasia, 662, 663
Lymphadenectomy, retroperitoneal, for testicular cancer. See *Testicular cancer.*
Lymphangiography, of prostatic cancer, as staging device, 855

Magnesium, excretion of, in hydronephrosis, in children, 311
Magnetic resonance imaging, of benign prostatic hyperplasia, 530–532
of prostatic cancer, as staging device, 855–856
of urolithiasis, 187–188
Meatal stenosis, in children, 329–331
Megaureters, management of, in children, **291–306**
definitions in, 291
diagnostic dilemma in, 293–294
evaluation in, 292–293
neonatal, 292
pathophysiology in, 294–296
postoperative evaluation in, 305–306
surgical objectives in, 296, 298–300
excising abnormal ureteral segment, 298
reimplanting revised megaureter, 298
remodeling megaureter, 298–300
surgical techniques for, 300–305
completion, 305
ureteral mobilization, 300–301
ureteral reimplantation, 301–304
ureteral revision, 301
Microsurgery, urologic, operating-table design in, **135–138**
advantages of, 137
applications of, 137–138
table construction, 135–137
Micturition. See *Voiding.*
Multichannel urodynamic studies, of benign prostatic hyperplasia, **543–552**
indications for, 543–544
videourodynamic studies, 547–551
vs. single-channel studies, 544–547
cystometry, 545
synchronous pressure-flow studies, 545–547
uroflowmetry, 545
Musculotropic relaxants, for neurogenic bladder dysfunction, in children, 400
Myomas, uterine, transcervical resection of, resectoscope in, **59–62**
clinical experience with, 60–61
history of uterine endoscopy and, 59
initial experience with, 59
postoperative management of, 59–60

N-acetylcysteine, for cystine calculi, 164, 223
Nephritis, acute interstitial, with nephrotic-range proteinuria, nonsteroidal anti-inflammatory drugs and, 151
Nephron hyperfiltration, and late onset renal failure, in children, 373–374
Nephrostomy, percutaneous, for posterior urethral valves, in children, 369
for staghorn calculi, 197–198
for ureteropelvic junction obstruction, in children, 422–423
introducer needle for, **91–93**
results of, 93
technique for, 91–93
Low-Profile Balloon Catheter in, **111–113**
Otis urethrotome in, **95–98**
dilation technique in, 95–96
instrumentation in, 95
results of, 96–97
Nephrotoxicity, of urologic drugs. See *Urologic drugs.*
Nephroureterectomy, for posterior urethral valves, in children, 370
Neurogenic bladder dysfunction, in children, **395–406**
detrusor-sphincter dyssynergia in, 402
hypertonic areflexic bladder in, 402

Neurogenic bladder dysfunction *(Continued)*
hypertonicity and hyperreflexia in, 402
identification of lower tract obstruction, 397–399
electromyography in, 398
pressure-flow studies in, 397–398
videourodynamics in, 398–399
medical therapy for, 399–400
pathophysiology of lower tract obstruction, 395–397
surgery for, 400–401
terminal hypertonicity in, 401–402
Nonsteroidal anti-inflammatory drugs, nephrotoxicity of, 150–151

Obesity, and extracorporeal shock wave lithotripsy, for renal calculi, 209–210
Obstructing ectopic ureteroceles, in children, **317–328**, 331
case reports of, 321–324
classification of, 317–318
clinical features of, 318
embryology of, 318
epidemiology of, 317
evaluation of, 318–321
Oligoanuria, cyclosporine and, 153
Oligohydramnios, and fetal hydronephrosis, 259
posterior urethral valves and, in children, 349, 351
Oncogenes, analysis of, in prostatic cancer, stage D1, 880–881
Orchiectomy, cosmetic, for prostatic cancer, **13–16**
results of, 15
technique for, 13
for prostatic cancer, complications of, 729
value of patient outcome in, 731
Orchiopexy, scrotal pouch, technique for, **9–12**
Organ Site Coordinating Center classification, of prostatic cancer, 689, 690
Orthoiodohippurate, iodine-131–labeled, in diuretic renography, 275
Otis urethrotome, in percutaneous nephrostomy. See *Nephrostomy.*
Outflow obstruction, benign prostatic hyperplasia and, 513–514
Oxybutynin chloride, for neurogenic bladder dysfunction, in children, 400

Papaverine hydrochloride, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 617–618
Passive urethral resistance relation, in voiding function, 559, 561, 564, 565
Pean artery forceps, in scrotal pouch orchiopexy, 9, 11
Pelvic kidneys, treatment of, 198
Pelvic lymph nodes, assessment of, in radial prostatectomy, for prostatic cancer, stage B, 780–782
Pelvic lymphadenectomy, to stage prostatic cancer, 856
Pelvimetrics, to measure hydronephrosis, in children, 265
Pelvioureterostomy-en-Y, for posterior urethral valves, in children, 340
Penicillamine, for cystine calculi, 164
Penile arteries, revascularization of, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 619
Penile-brachial index, in impotence, due to prostatectomy, for benign prostatic hyperplasia, 616
Penile prostheses, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 619–620
Penile veins, evaluation of, in impotence, due to prostatectomy, for benign prostatic hyperplasia, 617
excision and ligation of, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 619
Percutaneous lithotripsy, for renal calculi. See *Renal calculi.*
Pharmacotherapy, intracavernous, tourniquet for, **19–21**
Phenoxybenzamine, for benign prostatic hyperplasia, clinical trials of, 644–645
Phentolamine, for benign prostatic hyperplasia, clinical trials of, 645–646
Plain films, of benign prostatic hyperplasia, 520–523
of urolithiasis, 174–177
Plain renal tomography, of urolithiasis, 174–177
Politano-Leadbetter technique, for implantation of revised megaureters, in children, 298
Polyhydramnios, and fetal hydronephrosis, 249
Polyps, urethral, in children, 330–331
Polyuria, posterior urethral valves and, in children, 375
Posterior urethral valves, and fetal hydronephrosis, 252–253
in children, 331, 332–333, **335–342**, **343–360**, **361–372**, **373–378**, **379–387**
and end-stage renal disease, 356–357
and hypertension and proteinuria, 357–358
and inadequate growth, 357
and incontinence, 358
and sexual and ejaculatory function, 359
diagnosis of, 367–368
early ureteral surgery for, **361–372**
azotemia and, 365–367
hydronephrosis and, 364–365
pathophysiology and, 361–362
urinary extravasation and, 363
urinary tract infection and, 363–364
vesicoureteral reflux and, 364
historical aspects of, 343–345
long-term monitoring of, 355–356
long-term status of, **373–378**
pathogenesis of late onset renal failure, 373–374
polyuria, 375
preservation of renal function, 375–376
renal and bladder function, 374–375
renal prognosis, 373
renal transplantation, 376
sexual function and fertility, 377
undiversion, 376–377
urinary incontinence after valve ablation, 374
postnatal management of, 352–355
prenatal management of, 337, 352
primary pathology of, 345, 350
prognosis for, 338–341
urinary diversion, 340–341
valve ablation, 339–340
secondary pathology of, 345–352
anatomic level of decompression, 351–352
detrusor storage capacity, 346–347
high urine output, 349
incidence of, 350
infection, 349
lung development, 349–350
oligohydramnios, 349
renal damage and destruction, 349
reversibility of, 351
severity of, 350–351
timing of intervention for, 351
ureteral function, 348–349
vesicoureteral reflux, 347–348
voiding efficiency, 345–346
transitional nephrology in, 335–336
treatment options for, historical aspects of, 337–338
undiversion and reconstruction for, 355

ureteral drainage in, 336
urinary incontinence after ablation of. See *Urinary incontinence.*
valve bladder syndrome in, 336–337
Prazosin, for benign prostatic hyperplasia, clinical trials of, 646, 653
for neurogenic bladder dysfunction, in children, 400
Pressure-flow diagram, of voiding function, 561–565
Pressure-flow relations, in voiding function, 555–556
Pressure-flow studies, in children, of neurogenic bladder dysfunction, 397–398
of posterior urethral valves, 368
of ureteropelvic junction obstruction, 268–269, 270
of benign prostatic hyperplasia, 545–547
for treatment response to drugs, 639
Progestational agents, for benign prostatic hyperplasia, effects of, 666
Prostate, anesthetization of, for transurethral balloon dilatation, **55–56**
cancer of. See *Prostatic cancer.*
embryology of, **487–493**
origin and properties of smooth muscle, 490–491
stromal-epithelial interactions in, 489–490
morphology of, 488–489
transurethral resection of, Hegar dilators in, **57–58**
Prostate-specific antigen, as screening test, for prostatic cancer, 725–726, 762–766
assays in, 762
before and after radical prostatectomy, **813–817**
for staging, 813–814
clinically occult, 569–570
establishment of normal range in, 762–763
performance characteristics of, 763–766
specimen collection issues in, 762
stage A, 771
stage B, 782–783
as staging marker, for prostatic cancre, 854
to direct adjunctive therapy, 843–844
Prostatectomy, open, for benign prostatic hyperplasia, antimicrobials in, 596–597
radical. See *Radical prostatectomy.*
transurethral. See *Transurethral prostatectomy.*
vs. radiotherapy, for clinically occult prostatic cancer, 571
Prostatic acid phosphatase, as screening test, for prostatic cancer, 725, 759–762
assays in, 760
clinically occult, 569
sensitivity of, 761–762
specimen collection issues in, 760
stage B, 782–783
as staging marker, for prostatic cancer, 854
measurement of, flow cytometry in, 889
Prostatic cancer, clinically occult, **567–574**
digital rectal examination of, 570
incidence of, in prostatectomy, for benign prostatic hyperplasia, 567–568
prostate-specific antigen in, 569–570
prostatic acid phosphatase in, 569
random biopsy of, 570–571
transrectal ultrasonography of, 568–569
treatment of, 571–572
cosmetic orchiectomy for. See *Orchiectomy.*
diagnosis of, digital rectal examination in. See *Digital rectal examination.*
laboratory studies in, **759–768**
future of, 766
prostate-specific antigen. See *Prostate-specific antigen.*
prostatic acid phosphatase. See *Prostatic acid phosphatase.*
transrectal ultrasonography in. See *Transrectal ultrasonography.*
epidemiology of, **709–718**
definitions in, 709–710
risk factors in, 710–715
age, 710
benign prostatic hyperplasia, 713
body size, 713–714
cadmium intake, 714
diet, 712–713
endocrinologic, 714–715
familial, 711–712
migratory factors, 711
physical size, 714
race, 710
sex hormone levels, 715
sexual activity, 714
vitamin A intake, 713
zinc intake, 714
flow cytometry in. See *Flow cytometry.*
localized, case for no initial treatment of, **827–834**
cost of intervention, 829–830
decision making in, 832–833
natural history in, 827–828
pathology in, 828–829
screening program in, 828
treatment failure in, **835–851**
adjunctive therapy for, prostate-specific antigen directed, 843–844
and distant metastases, 845–846
antiandrogen therapy for, 845
biopsy data on, 837–838
clinical data on, 838–839
future of, 848
morbidity and mortality with, 846–848
prophylactic therapy for, 841–843
radical prostatectomy, 839–840
radiotherapy, 835–837, 839
low-stage, natural history and early detection of, **689–697**
clinical tumor progression in, 690–693
definitions in, 689–690
host-tumor interaction in, 696
impact of early detection, 694–695
radical prostatectomy for. See *Radical prostatectomy.*
radiotherapy for. See *Radiotherapy.*
screening programs for, **698–708**
cost effectiveness of, 705–707
definitions in, 698
economics of, **719–737**
clinical decision analysis model in, 720–721
for confirmation and staging, 726–727
for digital rectal examination, 724, 727
for prostate-specific antigen, 725–726
for prostatic acid phosphatase, 725
for transrectal ultrasonography, 724–725
patient population in, 721
results in, 732–735
selection of treatment modality in, 727–729
value of patient outcomes in, 729–732
randomized controlled trials in, 701–705
stage A, **769–777**
detection of nonpalpable tumors, 770–771
incidence and definitions in, 769–770
natural history of, 771–773
radical prostatectomy for, 774–775
radiotherapy for, 775–776
repeat transurethral resection for, 773–774

Prostatic cancer *(Continued)*
stage B, radical prostatectomy for. See *Radical prostatectomy.*
stage C, **853–866**
definition of, 853
hormone therapy for, 857–858
incidence and prognosis of, 854
radical prostatectomy for, 858–859
radiotherapy for, 859–862
staging of, 854–856
transurethral prostatectomy for, 856–857
stage D1, **867–884**
cell receptor and oncogene analysis in, 880–881
chemotherapy for, 879–880
endocrine therapy for, 873–874
with surgery, 874–876
flow cytometry for, 880
hormone therapy for, 872–873
natural history of, 868–871
influence of positive seminal vesicles and nodal volume, 869
use of delayed hormonal suppression, 869–871
radiotherapy for, 876–879
with chemotherapy, 879
with hormonal therapy, 878–879
staging and diagnosis of, 867–868
surgical treatment of, 871–872
with endocrine therapy, 874–876
Prostatic urethra, in prune belly syndrome, in children, 408–409
Prostheses, penile, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 619–620
Proteinuria, nephrotic-range, with acute interstitial nephritis, nonsteroidal anti-inflammatory drugs and, 151
posterior urethral valves and, in children, 357–358
Prune belly syndrome, and fetal hydronephrosis, 253
postnatal management of, 260
in children, **407–418**
extensive surgical remodeling for, 411
imaging of, 409
internal urethrotomy for, 412
nonoperative therapy for, 411
urinary tract anatomy in, 408–409
vesicostomy for, 411
Psychotherapy, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 617
Pubis, splitting of, for urinary incontinence. See *Urinary incontinence.*
Pulsed dye laser therapy, for ureteral calculi, 201, 219–220, 226–227
Pyelostomy, for posterior urethral valves, in children, 354, 355, 369

Radical prostatectomy, **679–684**
anatomy in, 679
complications of, 728
control of dorsal vein complex in, **49–53**
technique for, 49–51
exposure of dorsal vein complex in, **47–48**
for prostatic cancer, local failure after, 839–840
positive margins or vesicle invasion after, **803–812**
case reports of, 803–810
effectiveness of treatment for, 808–809
necessity of treatment for, 808
radiotherapy for, safety of, 809
potency-sparing, **819–826**
categories of, results of, 820
completeness of tumor excision in, 820–821
goals of, 820–822
patient selection for, 820
technique for, 819
prostate-specific antigen in, **813–817**
for staging, 813–814
to detect recurrence, 814–817
stage A, 774–775
stage B, **779–785**
life expectancy and tumor progression in, 784
pelvic lymph node assessment in, 780–782
prostate-specific antigen in, 782–783
prostatic acid phosphatase in, 782–783
transrectal ultrasonography in, as adjunct to digital rectal examination, 783–784
tumor ploidy in, 783
stage C, 858–859
value of patient outcome in, 730–731
results of, 682–684
technique for, 681–682
Radiographic contrast media, nephrotoxicity of, 149–150
Radionuclide renography, of urolithiasis, 186–187
Radiotherapy, for prostatic cancer, after radical prostatectomy, 816–817
complications of, 728–729
follow-up of, **787–802**
materials and methods in, 788–789
results of, 789–800
statistical presentation of, 789–790
survival, 790–791, 796, 800
for positive margins or vesicle invasion, after radical prostatectomy, 809
local failure after, 835–836, 839
stage A, 775–776
stage C, 859–862
stage D1, 876–879
with chemotherapy, 879
with hormone therapy, 878–879
value of patient outcome in, 731
vs. prostatectomy, for clinically occult prostatic cancer, 571
Rectal injury, radical prostatectomy and, for prostatic cancer, 728
radiotherapy and, for prostatic cancer, 728
5α-Reductase inhibitor therapy, for benign prostatic hyperplasia, effects of, 666–669
Renal allografts, calculi in, 202
Renal calculi, percutaneous procedures for, **207–216**
certainty of final results of, 212
contraindications to, 208
in children, 212
in cystine calculi, 211–212
in staghorn calculi, 209
in ureteral stones, 214–215
indications for, 207–208
large stone volume and, 208–209
obesity and, 209–210
obstructive uropathy and, 215–216
other-modality failure and, 213–214
treatment options for, 193–198
in caliceal calculi, 195–196
in caliceal diverticula and infundibular stenosis with stones, 194–195
in horseshoe kidneys, 198
in pelvic kidneys, 198
in staghorn calculi, 196–198
in stones other than staghorn calculi, 193–194
Renal dysfunction, posterior urethral valves and, in children, 362
Renal failure, benign prostatic hyperplasia and, 504, 523
posterior urethral valves and, in children. See *Posterior urethral valves.*

Renal function, vesicoureteral reflux and, in children. See *Vesicoureteral reflux.*
Renal papillary necrosis, and chronic tubulointerstitial disease, nonsteroidal anti-inflammatory drugs and, 151
Renal pelvis, catheter drainage of, Low-Profile Balloon Catheter in, **111–113**
Renal transplantation, for posterior urethral valves, in children, 376
Renography, diuretic. See *Diuretic renography.*
  radionuclide, of urolithiasis, 186–187
Resectoscope, constant-flow, in transurethral prostatectomy, for benign prostatic hyperplasia, 580
  for colonic cancer. See *Colonic cancer.*
  for transcervical resection of uterine myomas. See *Myomas.*
Residual urine, benign prostatic hyperplasia and, and treatment response to drugs, 638, 644
Retrograde urethrography, of benign prostatic hyperplasia, 523–524
Retroperitoneal lymphadenectomy, for testicular cancer. See *Testicular cancer.*

Sclerosing agents, in spermatic veins, for varicoceles, 902, 904
Scrotal pouch orchiopexy, technique for, **9–12**
Sex hormones, levels of, and risk of prostatic cancer, 715
Sexual function, posterior urethral valves and, in children, 377
Sodium bicarbonate, for uric acid calculi, 223
Sodium cellulose phosphate, for calcium calculi, 167
Spermatic veins, percutaneous transcatheter occlusion of, for varicoceles, 898–900, 902, 904–905
Staghorn calculi, percutaneous procedures for, 209
  treatment of, 196–198
Steinstrasse, treatment of, 201–202, 226
Steroids, for urethral strictures, in children, 392
Stirrups, modified, for dorsal lithotomy, **131–133**
Stomal stenosis, ileocutaneous, correction of, 128–129
Stone baskets, for ureteral calculi, **81–82**, 224–225
Stone disease. See also *Calculi; Urolithiasis.*
  treatment of, in children, 203
Strictures, radiotherapy and, for prostatic cancer, 729
  ureteral. See *Ureteral strictures.*
  urethral. See *Urethral strictures.*
Struvite calculi, chemolysis of, 221
  diagnostic imaging of, 177
  metabolic evaluation of, 161–162
  treatment of, 164–165
Suby's solution, for struvite calculi, 164–165

Technetium-99m-DTPA, in diuretic renography, 274–275, 276, 278, 279–280, 319
  in kidney function studies, 310
Technetium-99m-EDTA, in kidney function studies, 310
Technetium-99m-glucoheptonate, in diuretic renography, 280–281
Technetium-99m-mercaptoacetyltriglycine, in diuretic renography, 275
Teflon paste, in orchiectomy, for prostatic cancer, 13, 16
Terazosin, for benign prostatic hyperplasia, clinical trials of, 653–656
Testicular cancer, retroperitoneal lymphadenectomy for, **449–456**
  anatomy in, 450
  complications of, 454–455
  indications for, 449–450
  patient preparation for, 451
  postoperative care for, 454
  results of, 455
  technique for, 451–454
Testosterone, in benign prostatic hyperplasia, 663–664
THAM-E, for cystine calculi, 223
  for uric acid calculi, 223
Thermal injury, to penis, during prostatectomy, and erectile failure, 615
Thiazides, for calcium calculi, 167
Tomography, plain renal, of urolithiasis, 174–177
Transrectal ultrasonography, of prostatic cancer, **745–757**
  anatomy in, 746–747
  as early detection device, 751–754
  as staging device, 754–755, 854–855
  clinically occult, 568–569
  echo pattern of normal tissue in, 747–748
  echo pattern of prostatic cancer in, 748–751
  economics of, 724–725
  historical aspects of, 745–746
  stage A, 770, 772–773
  stage B, as adjunct to digital rectal examination, 783–784
Transurethral incision, for benign prostatic hypertrophy, vs. transurethral prostatectomy. See *Transurethral prostatectomy.*
Transurethral prostatectomy, for benign prostatic hyperplasia, **575–585**
  anesthesia for, 577–578
  antimicrobials in, **595–600**
    bacteriology of infections, 597, 599
    choice, dose, and duration of, 599
    factors increasing complications of, 597
    sources and incidences of infections, 595–596
    studies and reviews of, 596–597
  AUA survey and Medicare reimbursement of, **587–593**
    costs, 588–590
    economic impact, 591–592
    future reimbursement, 591
    past reimbursement, 590–591
    role in American urology, 587
  constant-flow resectoscope in, 580
  historical aspects of, 575–577
  impotence after. See *Impotence.*
  irrigating fluids in, 581–582
  long-term follow-up of, 583–584
  preoperative evaluation for, 577
  results of, 582–583
  suprapubic drainage in, 580–581
  technique for, 578–580
  vs. terazosin, 656
  vs. transurethral incision, **601–612**
    cost reduction in, 609
    definitions and terminology of, 602–603
    diagnosis of bladder outlet obstruction in, 606
    fee collection in, 608–609
    indications for, 603–604
    patient selection for, 604, 606
    randomized study of, **621–630**
      patients and methods in, 621–623
      results of, 623–627
    silent consent in, 611
    technique for, 606–608
    unnecessary surgery in, 609, 611
  for prostatic cancer, stage C, 856–857
Transurethral resection, for prostatic cancer, stage A, 773–774
Trauma, to penis, during prostatectomy, and erectile failure, 615

Tricyclic antidepressants, for neurogenic bladder dysfunction, in children, 400
Tromethamine-E, for cystine calculi, 223
for uric acid calculi, 223
Tubulointerstitial disease, and renal papillary necrosis, nonsteroidal anti-inflammatory drugs and, 151

Ultrasonography, in children, in-office, of urinary tract obstruction, **429–435**
materials and methods for, 429
results of, 429–432
of obstructing ectopic ureteroceles, 318
of posterior urethral valves, 352–353, 367–368
of benign prostatic hyperplasia, 524, 526–530
of impotence, due to prostatectomy, for benign prostatic hyperplasia, 616–617
of urolithiasis, 183–185
prenatal, of hydronephrosis, 247–248
of posterior urethral valves, 352
to localize calculi, for extracorporeal shock wave lithotripsy, 225–226, 233–234
transrectal. See *Transrectal ultrasonography.*
Undiversion, for posterior urethral valves, in children, 355, 376–377
Ureter, calculi in. See *Ureteral calculi.*
endoscopic occlusion of, for lower urinary tract fistulas. See *Fistulas.*
guide-eye access system for, **75–79**
applications of, 77–79
benefits of, 76–77
limitations of, 75
replacement of, vesicoureteral reflection for, **121–123**
materials and methods in, 121
results of, 121–122
Ureteral calculi, 198–202, **217–230**
blind stone basketing for, 224–225
controllable stone baskets for, **81–82**
electrohydraulic lithotripsy for, 201, 220, 227–228
extracorporeal shock wave lithotripsy for, 198–202, 217–219, 224, 228–229
in distal third, 200–201
in middle third, 199–200, 224
in upper third, 198–199, 217–223
intramural, 202
laser lithotripsy for, 226–227
percutaneous procedures for, 214–215
pulsed dye laser therapy for, 201, 219–220
Steinstrasse, 201–202, 226
ultrasonic lithotripsy for, 225–226
ureteroscopic extraction of, 225
ureteroscopic fragmentation of, 225
ureteroscopy of, 199–201, 219–221, 223
Ureteral strictures, coaxial knife for, **83–89**
advantages of, 87
backloading of, 87
case reports of, 84–85
design and construction of, 83–84
Ureterectomy, for obstructing ectopic ureteroceles, in children, 321
Ureteroceles, obstructing ectopic. See *Obstructing ectopic ureteroceles.*
Ureteroileal calculi, treatment of, 202–203
Ureterolithotomy, for ureteral calculi, 223
Ureteropelvic junction obstruction, and fetal hydronephrosis, 249
in children, **419–428**
endopyelotomy for, 421, 422, 423–426
complications of, 425–426
endourologic procedures for, 420–422
open operations for, 419–420
pathophysiology of, **263–272**
anatomic abnormalities in, 266–267
and hydronephrosis, 264–266
diuretic renography of. See *Diuretic renography.*
pressure-flow studies of, 268–269, 270
urodynamic characteristics in, 267
percutaneous nephrostomy for, 422–423
Ureteropyelography, of urolithiasis, 180, 182–183
Ureteropyelostomy, for obstructing ectopic ureteroceles, in children, 320
Ureterorenoscopy, of ureteral calculi, 224
Ureteroscopy, of ureteral calculi, 199–201, 219–221, 223
Ureterostomy, for posterior urethral valves, in children, 340, 369–370
Ureteroureterostomy, for obstructing ectopic ureteroceles, in children, 320–321
Ureterovesical junction obstruction, and fetal hydronephrosis, 249
and posterior urethral valves, in children, 361–362
Ureters, dilated obstructed. See *Megaureters.*
function of, posterior urethral valves and, in children, 348–349
in prune belly syndrome, in children, 408
obstruction of, experimental models of, 439–440
Urethra, indwelling catheterization of, patient comfort in, **23–24**
obstruction of, in children, 329–331
polyps of, in children, 330–331
prostatic, in prune belly syndrome, in children, 408–409
Urethral profilometry, of benign prostatic hyperplasia, for response to alpha-adrenergic blockers, 644
Urethral strictures, Goodwin sound for, **31–34**
history of posterior urethroplasty and, 31
indications for, 32
technique for, 32
in children, **389–394**
clinical features of, 390
diagnosis of, 390
etiology of, 389–390
experimental findings on, 390–391
manipulation of, 392
repair of, 392–393
temporary diversion for, 391–392
intraoperative endourologic manipulation of, **25–29**
catheter placement after prostate resection, 26
during prostate resection, 25–26
materials and methods in, 25
transvesical endoscopic suture placement for, **35–36**
Urethrography, retrograde, of benign prostatic hyperplasia, 523–524
technique for, 7
Urethroscopy, instruments for, 5–7
Urethrotome, Otis, in percutaneous nephrostomy. See *Nephrostomy.*
Urethrotomy, for urethral strictures, in children, 392
internal, for prune belly syndrome, in children, 412
Uric acid calculi, chemolysis of, 223
diagnostic imaging of, 177
metabolic evaluation of, 162
treatment of, 163–164, 193
Urinary diversion, for posterior urethral valves, in children, 340–341
lower urinary tract fistulas and. See *Fistulas.*
Urinary drainage bag, design of, **141–143**
Urinary extravasation, posterior urethral valves and, in children, 363

Urinary incontinence, after posterior urethral valve ablation, in children, **379–387**, 374
incidence of, 379–380
management of, 384–386
pathogenesis of, 382–384
urodynamic evaluation of, 380–382
posterior urethral valves and, 358
radical prostatectomy and, for prostatic cancer, 728
radiotherapy and, for prostatic cancer, 728–729
reconstructive surgery for, splitting of pubis in, **37–45**
case reports of, 39
clinical experience with, 39, 41–42
technique for, 37–39
Urinary retention, benign prostatic hyperplasia and, 503–504, 510, 514
and response to alpha-adrenergic blockers, 644
Urinary tract, infection of, benign prostatic hyperplasia and, 504
posterior urethral valves and, in children, 349, 363–364
vesicoureteral reflux and, in children, 313
lower, fistulas of. See *Fistulas*.
obstruction of, in children, **329–334**
bladder abnormalities and, 331–333
pathophysiology of, 329
urethral, 329–331
in-office ultrasonography of. See *Ultrasonography*.
upper, duplex anomalies of, and fetal hydronephrosis, 249, 252
radioisotopic evaluation of, in children, **273–289**
algorithm for, 282–287
equivocal study, 283
evident obstruction, 287
no evident obstruction, 283
probable obstruction, 283, 286–287
diuretic renography in. See *Diuretic renography*.
individual kidney function in, 279–282
radioisotope transit time in, 279
Urine, concentration of, vesicoureteral reflux and, in children, 312–315
output of, posterior urethral valves and, in children, 349
residual, benign prostatic hyperplasia and, 511
and treatment response to drugs, 638, 644
Urodynamics, of posterior urethral valves, in children, 380–382
of voiding function. See *Voiding*.
video, of neurogenic bladder dysfunction, in children, 398–399
Uroflowmetry, of benign prostatic hyperplasia, 514, **537–542**, 545
abnormal flow rate in, 540–541
examination technique for, 538–539
for response to alpha-adrenergic blockers, 644
for treatment response to drugs, 637–638
limitations of, 541–542
measurement principles and techniques for, 537–538
relation of flow rate, intravesical volume, and contraction velocity, 540
results of, 539–540
Urography, intravenous, of benign prostatic hyperplasia, 520–523
of urolithiasis, 177–180
Urolithiasis, diagnosis and decision making in, **171–190**
antegrade and retrograde ureteropyelography in, 180, 182–183
arteriography and magnetic resonance imaging in, 187–188
choice of treatment method, 172, 173–174
computed tomography in, 185–186
extraurinary factors in, 173
indications for intervention, 171–172
intravenous urography in, 177–180
to assess degree of obstruction, 178–179
plain films and plain renal tomography in, 174–177
radionuclide renography in, 186–187
stone factors in, 172–173
ultrasonography in, 183–185
uroradiographic features in, 173
metabolic evaluation of, **159–169**
calcium calculi, 159–161, 165, 167
cystine calculi, 162
definitions in, 159
patient selection for, 163
struvite calculi, 161–162
theories of stone formation, 162–163
uric acid calculi, 162
treatment options for, **191–206**
in combination stones, 203
in kidney stones. See *Renal calculi*.
in pediatric stone disease, 203
in stones in renal allograft, 202
in ureteral calculi. See *Ureteral calculi*.
in ureteroileal stones, 202–203
stone composition and, 192–193
Urologic diagnostic techniques, in females, **5–8**
urethrography, 7
urethroscopy, 5–7
vaginoscopy, 5
Urologic drugs, nephrotoxicity of, **145–156**
aminoglycoside antibiotics, 146–148
amphotericin B, 148–149
cisplatin and carboplatin, 151–152
cyclosporine, 152–154
mechanisms of, 145–146
nonsteroidal anti-inflammatory agents, 150–151
radiographic contrast media, 149–150
Uropathy, congenital obstructive. See *Congenital obstructive uropathy*.
obstructive, and renal calculi, 215–216
Uterus, myomas of. See *Myomas*.

Vacuum erection devices, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 618–619
Vaginoscopy, technique for, 5
Varicoceles, **893–907**
anatomy of, 894–895
diagnosis of, 893–894
pathophysiology of, 895
treatment of, complications of, 905
indications for, 895
risks and benefits of, 904–905
surgical, 896–898, 904–905
percutaneous transcatheter occlusion of spermatic veins, 898–900, 902, 904–905
Vasectomy, to prevent epididymitis, after transurethral prostatectomy, for benign prostatic hyperplasia, 581
Vasoactive drugs, for impotence, due to prostatectomy, for benign prostatic hyperplasia, 617–618
intracavernous, tourniquet for, **19–21**
Vesical augmentation, for posterior urethral valves, in children, 341
Vesicostomy, in children, for neurogenic bladder dysfunction, 401, 402
for posterior urethral valves, 340, 368–369
for prune belly syndrome, 411
for urethral strictures, 392
Vesicoureteral reflux, and fetal hydronephrosis, 252

Vesicoureteral reflux *(Continued)*
in children, and obstructing ectopic ureteroceles, 321
and renal functional changes, **307–316**
acid-base balance, 311–312
concentrating ability, 312–315
glomerular filtration, 309–310
renal tubular actions, 310–311
posterior urethral valves and, 347–348, 351, 364, 374
vs. partial ureteral obstruction, 307–309
Videourodynamic studies, of benign prostatic hyperplasia, 547–551
of neurogenic bladder dysfunction, in children, 398–399
Vitamin A, intake of, and risk of prostatic cancer, 713
Voiding, efficiency of, posterior urethral valves and, in children, 345–346
urodynamic analysis of, **553–566**
clinical definition of obstruction, 558–559
concepts of data analysis, 559–561
energy balance of micturition, 556–557
pressure-flow diagram in, 561–565
principles of voiding mechanics, 553–556
specific types of obstruction, 557–558
Voiding cystourethrography, of benign prostatic hyperplasia, 523–524
of obstructing ectopic ureteroceles, in children, 318
of posterior urethral valves, in children, 353, 367

Whitaker test. See *Pressure-flow studies.*

YM-12617, for benign prostatic hyperplasia, 653–654, 656

Zinc, intake of, and risk of prostatic cancer, 714